Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. Our lead program uses Heidelberg Pharma’s proprietary ATAC technology embracing innovative antibody design, linker technology and the payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers.
This approach brings the promise of superiority to enfortumab vedotin, a high-profile ADC for urothelial cancer which received US FDA accelerated approval in December 2019. We are also exploring opportunities to develop a broader pipeline of additional best- or first-in-class ADCs driven by therapeutic need.
Emergence is led by a strong management team supported by a network of world-leading experts in immuno-oncology and leading European investors.